Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 

In pursuit of biomarkers
May 2019
SHARING OPTIONS:

BOULDER, Colo.—A new collaborative agreement is underway between SomaLogic Inc. and Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson centered on precision health. Per the agreement, SomaLogic will analyze approximately 5,000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate proteins biomarkers that could be used in the prediction, diagnosis, monitoring and treatment of disease. Indications will include—but not be limited to—rheumatoid arthritis, inflammatory bowel disease, lupus, and cardiovascular and metabolic conditions. Specific details were not released.
 
“We are happy that the Janssen research teams are exploring the potential of our protein-measurement platform for their drug discovery and development efforts,” said Roy Smythe, SomaLogic CEO. “We prefer this kind of ‘win-win’ collaboration, where each party shares data and expertise with the other in an effort to achieve the high-value goal of more rapidly advancing healthcare.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.